Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab maintenance therapy after fludarabine + cyclophosphamide as second-line treatment in chronic lymphocytic leukemia
2004-005049-36Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AOU Città della Salute e della Scienza di Torino. Started Jul 2005; status: active.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2004-005049-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005049-36.